Neumora Therapeutics, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.37
- 52-Week Range
- $0.30 – $3.65
- Market Cap
- $65.48M
- P/E (TTM)
- —
- EPS (TTM)
- -1.06
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.54
- PEG Ratio
- —
- Return on Equity
- -252.71%
- Return on Assets
- -85.63%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 4.08
- Debt/Equity
- 2.89
- Total Debt
- $53.57M
- Free Cash Flow
- $-97.67M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $33.39M
Market Snapshot
About
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain diseases. The company uses precision medicine approaches and biomarker-driven strategies to address neuropsychiatric and neurodegenerative disorders.